India may be adding more trade partners, but its latest FTA report card comes with several red marks. A new study by the Global Trade Resea...

India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...

India is ready to welcome high-quality global pharmaceutical products. This move is in exchange for better market access for Indian drug ex...

Even in normal times it is futile to try and guess the outcome of most global events. But in the New World Order, it makes no sense at all ...

As India accelerates its sovereign AI ambitions, the focus is shifting from infrastructure to outcomes, how businesses can harness AI to im...

India's drug regulator, CDSCO, has mandated all drug companies to establish systems for tracking adverse drug reactions. This move comes am...

For the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...

Indian pharma exports to the US face a subdued outlook this year. Policy uncertainties, falling generic prices, and regional conflicts are ...

Aurobindo Pharma has launched TheraNym, a major biologics manufacturing plant in Telangana. This facility will produce biologic medicines f...

As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...

Indian companies achieved better-than-expected profits in the March quarter. Domestic activity was strong, supported by tax cuts and easy m...

This partnership aims to accelerate Rosada's expansion and solidify its presence in the premium children's market. The investment will fuel...

After the correction, the street will reach a stage where, if a company delivers numbers, there will be enough money waiting to move into t...

The leader of opposition in the Lok Sabha said Prime Minister Modi's silence on the Central Board of Secondary Education's (CBSE) On-Screen...

There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...

Cipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...